Essential hypertension

3 trials 1 recruiting MedDRA PT
3 Registered trials
1 Recruiting
3 Unique sponsors
4 Unique IMPs
2 Commercial trials
Drug classes (ATC)
ATC code not specified 2
C Cardiology (ATC C) 1
Mechanism of action (INN-stem analysis)
ARB 2 substances
Calcium channel blocker 1 substance
Unknown / small molecule 1 substance
Phase IV: 1 Other: 2

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase IV

1 trial
  • Stichting Radboud University Medical Center Academic
    AMLODIPINE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL; OLMESARTAN MEDOXOMIL, AMLODIPINE
    2023-505239-10-00 1 country 2024 n=66
    Recruiting

Other

2 trials
  • Pharma Start LLC Commercial
    IMP not specified
    2025-523054-14-00 1 country 2025 n=42
    Ended
  • Zaklady Farmaceutyczne Polpharma S.A. Commercial
    IMP not specified
    2024-514456-32-00 1 country 2024 n=72
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Pharma Start LLC Commercial 1 Other 0
Zaklady Farmaceutyczne Polpharma S.A. Commercial 1 Other 0
Stichting Radboud University Medical Center Academic 1 Phase IV 1
New trials by year
2024
2
2025
1
← All indication landscapes